Home Tags AstraZeneca

Tag: AstraZeneca

What are the next generation ADCs?

In the last decade, there have unprecedented advances in discovery of new cytotoxic warheads of different mechanisms, new linkers with highly stable DARs, warhead...

Successful Funding Round Expected to Accelerate ADC Therapeutics’ Clinical Development

Swiss Biotech company ADC Therapeutics, an oncology drug discovery and development company specializing in the development of proprietary antibody-drug conjugates or ADCs for the treatment...

Comparison of Three Different PD-L1 Diagnostic Tests Shows a High Degree of...

Three commercially available diagnostic tests were similarly effective in measuring PD-L1 protein expression on non-small cell lung cancer (NSCLC) tumor samples, indicating that health...

Regeneron and MedImmune Sign Licensing Agreement for Pyrrolobenzodiazepine-based Payload and Linker...

This month Regeneron Pharmaceuticals, a science-based biopharmaceutical company based in Tarrytown, New York and MedImmune, the global biologics research and development arm of AstraZeneca  entered...

London Calling: The Cutting-edge of Novel ADC Technologies

Major players in the rapidly advancing field of antibody drug conjugates (ADCs) will meet in London, United Kingdom, on 23-24 May for the annual...

AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases...

ADC Therapeutics Raises US$ 80 million to Advance ADC Pipeline

ADC Therapeutics, an oncology drug discovery and development company headquartered in Lausanne, Switzerland and London, UK, that specializes in the development of proprietary Antibody...